>
MacroGenics Inc logo

MGNX - MacroGenics Inc Share Price

$20.84 1.1  5.6%

Last Trade - 7:46pm

Sector
Healthcare
Size
Mid Cap
Market Cap £881.6m
Enterprise Value £664.3m
Revenue £86.7m
Position in Universe 2795th / 7172
Bullish
Bearish
Unlock MGNX Revenue
Momentum
Relative Strength (%)
1m -12.1%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -45.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
100.9 91.9 157.7 60.1 64.2 104.9 109.6 130.2 +0.8%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 30 June 2021, MacroGenicsInc revenues increased 40% to $47.6M. Net loss increasedless than 1% to $91.2M. Revenues reflect Revenue fromcollaborative and other agr increase of 48% to $42.4M.,offset by General and administrative - Balancing increaseof 55% to $24.7M (expense), Research&development-Bal Valincrease of 2% to $103.1M (expense), Stock-basedCompensation in SGA increase of 22% to $5.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for MGNX
Graphical History

Revenue

MGNX Revenue Unlock MGNX Revenue

Net Income

MGNX Net Income Unlock MGNX Revenue

Normalised EPS

MGNX Normalised EPS Unlock MGNX Revenue

PE Ratio Range

MGNX PE Ratio Range Unlock MGNX Revenue

Dividend Yield Range

MGNX Dividend Yield Range Unlock MGNX Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
MGNX EPS Forecasts Unlock MGNX Revenue
Profile Summary

MacroGenics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies. It has a pipeline of product candidates in human clinical testing, primarily as treatments for different types of cancers, which are created using its technology platforms. Its clinical product candidate, margetuximab, has been enhanced using its Fc Optimization platform. The Company is also developing several product candidates targeting B7-H3, a protein in the B7 family of immune regulator proteins. The Company's product candidates also include enoblituzumab and MGD009, MGC018, MGD006 (flotetuzumab), MGD007, MGD011 (duvortuxizumab), PF-06671008 and MGD010.

Directors
Last Annual December 31st, 2020
Last Interim June 30th, 2021
Incorporated August 14, 2000
Public Since October 10, 2013
No. of Shareholders: 63
No. of Employees: 370
Sector Healthcare
Industry Biotechnology & Medical Research
Index Nasdaq Composite ,
Exchange NASDAQ Global Select Market
Shares in Issue 61,107,288
Free Float (0.0%)
Eligible for
ISAs
SIPPs
MGNX Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for MGNX
Upcoming Events for MGNX
Thursday 30th September, 2021
MacroGenics Inc at Cantor Fitzgerald Global Healthcare Conference (Virtual)
Tuesday 2nd November, 2021 Estimate
Q3 2021 MacroGenics Inc Earnings Release
Wednesday 23rd February, 2022 Estimate
Q4 2021 MacroGenics Inc Earnings Release
Frequently Asked Questions for MacroGenics Inc
What is the MacroGenics Inc share price?

As of 7:46pm, shares in MacroGenics Inc are trading at $20.84, giving the company a market capitalisation of £881.6m. This share price information is delayed by 15 minutes.

How has the MacroGenics Inc share price performed this year?

Shares in MacroGenics Inc are currently trading at $20.84 and the price has moved by -20.05% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MacroGenics Inc price has moved by -40.72% over the past year.

What are the analyst and broker recommendations for MacroGenics Inc?

Of the analysts with advisory recommendations for MacroGenics Inc, there are there are currently 4 "buy" , 1 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MacroGenics Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will MacroGenics Inc next release its financial results?

MacroGenics Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2022-06-30
What is the MacroGenics Inc dividend yield?

MacroGenics Inc does not currently pay a dividend.

Does MacroGenics Inc pay a dividend?

MacroGenics Inc does not currently pay a dividend.

When does MacroGenics Inc next pay dividends?

MacroGenics Inc does not currently pay a dividend.

How do I buy MacroGenics Inc shares?

To buy shares in MacroGenics Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MacroGenics Inc?

Shares in MacroGenics Inc are currently trading at $20.84, giving the company a market capitalisation of £881.6m.

Where are MacroGenics Inc shares listed? Where are MacroGenics Inc shares listed?

Here are the trading details for MacroGenics Inc:

Country of listing: United States
Exchange: NSQ
Ticker Symbol: MGNX
What kind of share is MacroGenics Inc?

Based on an overall assessment of its quality, value and momentum, MacroGenics Inc is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a MacroGenics Inc share price forecast 2021?

Shares in MacroGenics Inc are currently priced at $20.84. At that level they are trading at 83.64% discount to the analyst consensus target price of 0.00.

Analysts covering MacroGenics Inc currently have a consensus Earnings Per Share (EPS) forecast of -2.953 for the next financial year.

How can I tell whether the MacroGenics Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MacroGenics Inc. Over the past six months, the relative strength of its shares against the market has been -46.93%. At the current price of $20.84, shares in MacroGenics Inc are trading at -23.63% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MacroGenics Inc PE Ratio?

We were not able to find PE ratio data for MacroGenics Inc.

Who are the key directors of MacroGenics Inc?

MacroGenics Inc's management team is headed by:

Scott Koenig - PRE
Ezio Bonvini - SVP
James Karrels - CFO
Paulo Costa - NEC
Eric Risser - SVP
Lynn Cilinski - VPR
Kenneth Galbraith - IND
Edward Hurwitz - IND
Karen Ferrante - IND
Scott Jackson - IND
Thomas Spitznagel - SVP
Jeffrey Peters - VPR
Stephen Eck - SVP
Who are the major shareholders of MacroGenics Inc?

Here are the top five shareholders of MacroGenics Inc based on the size of their shareholding:

Bellevue Asset Management AG Investment Advisor
Percentage owned: 12.07% (7.38m shares)
RA Capital Management, LP Hedge Fund
Percentage owned: 9.73% (5.94m shares)
BB Biotech Fd Mutual Fund
Percentage owned: 8.3% (5.07m shares)
BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 7.2% (4.40m shares)
Wasatch Global Investors Inc Investment Advisor/Hedge Fund
Percentage owned: 6.74% (4.12m shares)
Similar to MGNX
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.